Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03592472 · ClinicalTrials.gov registry record · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
A Phase 3 study of Renal Cell Carcinoma, sponsored by Xynomic Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 413
- Enrollment target
- 20
- Study locations
NCT03592472 is a Phase 3 study of Renal Cell Carcinoma that is actively recruiting participants, run by Xynomic Pharmaceuticals. The registered enrollment target is 413 participants, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (72% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT03592472, a Phase 3 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Xynomic Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 413 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Pazopanib
- DRUG Abexinostat
Study Locations (20)
Other
- Beijing Cancer Hospital - Beijing
- Zhongshan Hospital Affiliated to Fudan University - Shanghai
- Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica - Candiolo
- A.O. Cannizzaro_UOS Oncologia Medica - Catania
- IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica - Meldola (FC)
- Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale - Milan
California
- University of California Davis Comprehensive Cancer Center - Sacramento
- UCSF Helen Diller Family Comphrensive Cancer Center - Hemato - San Francisco
Nebraska
- GU Research Network/Urology Cancer Center - Omaha
- Nebraska Cancer Specialists - Omaha
New York
- Northwell Health/Monter Cancer Center - Lake Success
- Mainstreet Physicans Care - Rochester
Arizona
- University Of UA Cancer Center(UACC)/DH-SJHMC - Phoenix
Kentucky
- Norton Cancer Institute, Norton Healthcare Pavilion - Louisville
Louisiana
- Ochsner Clinic Foundation - New Orleans
Ohio
- Precision Cancer Research/Dayton Physicians Network - Treatment - Kettering
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03592472
The ClinicalTrials.gov registry entry for NCT03592472 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 413 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 240-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (72% higher). The listed sponsor is Xynomic Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03592472 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT03592472 about?
NCT03592472 is a clinical study titled "A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)". This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).
What is the current status of trial NCT03592472?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 413 participants. The study started on 2018-07-17. Estimated completion is 2028-06-30.
What conditions does trial NCT03592472 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT03592472?
The interventions under investigation include: Placebo (OTHER), Pazopanib (DRUG), Abexinostat (DRUG).
Who is sponsoring clinical trial NCT03592472?
This trial is sponsored by Xynomic Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03592472 being conducted?
This trial has 20 study locations across Arizona, California, Kentucky, Louisiana, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.